Sharon Benoit joins INC Research
This article was originally published in Scrip
The contract research organisation INC Research has appointedSharon Benoit principal strategist for infectious disease. She will provide strategic and development consultation to pharmaceutical customers and lead the CRO's virology teams in Phase I-IV trials. Ms Benoit has more than 20 years' experience in virology drug development, with particular focus on HIV and hepatitis. She most recently founded and served as the president of another CRO, and has also held clinical management positions at Glaxo Research Institute, Burroughs Wellcome and the Research Triangle Park Institute.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.